A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112478 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Xueying Zuo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, Ji…. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Mice, Inbred C57BL, Interferon Type I, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 82 Literaturangaben.
Abstract (Originalsprache)
Despite the groundbreaking impact of immune checkpoint blockade (ICB), response rates in non-small cell lung cancer remain modest, particularly in immune-excluded or immune-desert microenvironments. Toll-like receptor 7 (TLR7) emerges as a latent target bridging innate and adaptive immunity, offering a promising avenue for combination therapies to augment ICB efficacy. Here, we explored the anti-tumor activity of the novel oral TLR7 agonist TQ-A3334 and its potential to enhance anti-programmed death ligand 1 (PD-L1) therapy through a combination strategy in a syngeneic murine lung cancer model. Oral administration of TQ-A3334 significantly alleviated tumor burden in C57BL/6J mice, modulated by type I interferon (IFN), and exhibited low toxicity. This therapy elicited activation of both innate and adaptive immune cells in tumor tissue, particularly increasing the abundance of CD8+ TILs through type I IFN pathway and subsequent CXCL10 expression. In vitro examinations validated that IFN-α-stimulated tumor cells exhibited increased secretion of CXCL10, conducive to the promoted trafficking of CD8+ T cells. Furthermore, combining TQ-A3334 with anti-PD-L1 treatment exceeded tumor control, with a further increase in CD8+ TIL frequency compared to monotherapy. These findings suggest that TQ-A3334 can mobilize innate immunity and promote T cell recruitment into the tumor microenvironment; a combination of TQ-A3334 and anti-PD-L1 antibodies can intensify the sensitivity of tumors to anti-PD-L1 therapy, which demonstrates significant potential for treating poorly immune-infiltrated lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, Jiangsu, China.
- Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, Nanjing 210008, Jiangsu, China.
- Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, Jiangsu, China. Electronic address: TangfengLv7210@nju.edu.cn.
- Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, Jiangsu, China. Electronic address: yong.song@nju.edu.cn.
Zitieren
APA
Zuo, X., Cheng, Q., Wang, Z., Liu, J., Lu, W., Wu, G., Zhu, S., Liu, X., Lv, T., & Song, Y. (2024). A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112478
Vancouver
Zuo X, Cheng Q, Wang Z, Liu J, Lu W, Wu G, et al. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112478
BibTeX
@article{Zuo2024,
author = {Zuo, Xueying and Cheng, Qinpei and Wang, Zimu and Liu, Jiaxin and Lu, Wanjun and Wu, Guannan and Zhu, Suhua and Liu, Xin and Lv, Tangfeng and Song, Yong},
title = {A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112478}
}
EUVIMED